FDA approves once-weekly dosing for Amgen’s Kyprolis in multiple myeloma treatment
The United States Food and Drug Administration (FDA) has granted approval for a new once-weekly dosing regimen of Amgen’s Kyprolis (carfilzomib) in combination with dexamethasone for patients with relapsed or refractory multiple myeloma. This new regimen, known as the once-weekly Kd70, involves administering Kyprolis at a dose of 70 mg/m². The approval follows the results […]